Novartis Says Patients Stick to Treatment Better With AirFluSal

Patients with asthma or a progressive lung disease are less likely to abandon treatment with Novartis AG’s AirFluSal Forspiro inhaler than with GlaxoSmithKline Plc’s Seretide Diskus, the Swiss drugmaker said, citing a one-year study.

With the Novartis device, patients showed a persistence rate of 23 percent, compared with 11 percent for the Glaxo one, according to the study, which relied on a German pharmacy database and whose results were published in the Journal of Allergy and Clinical Immunology: In Practice.

    Before it's here, it's on the Bloomberg Terminal.